{
    "title": "Ensuring Patient Access and Effective Drug Enforcement Act of 2014",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Ensuring Patient Access and \nEffective Drug Enforcement Act of 2014''.\n\nSEC. 2. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.\n\n    (a) Definitions.--\n            (1) Factors as may be relevant to and consistent with the \n        public health and safety.--Section 303 of the Controlled \n        Substances Act (21 U.S.C. 823) is amended by adding at the end \n        the following:\n    ``(i) In this section, the phrase `factors as may be relevant to \nand consistent with the public health and safety' means factors that \nare relevant to and consistent with the findings contained in section \n101.''.\n            (2) Imminent danger to the public health or safety.--\n        Section 304(d) of the Controlled Substances Act (21 U.S.C. \n        824(d)) is amended--\n                    (A) by striking ``(d) The Attorney General'' and \n                inserting ``(d)(1) The Attorney General''; and\n                    (B) by adding at the end the following:\n    ``(2) In this subsection, the phrase `imminent danger to the public \nhealth or safety' means that, in the absence of an immediate suspension \norder, controlled substances--\n            ``(A) will continue to be intentionally distributed or \n        dispensed--\n                    ``(i) outside the usual course of professional \n                practice; or\n                    ``(ii) in a manner that poses a present or \n                foreseeable risk of serious adverse health consequences \n                or death; or\n            ``(B) will continue to be intentionally diverted outside of \n        legitimate distribution channels.''.\n    (b) Opportunity To Submit Corrective Action Plan Prior to \nRevocation or Suspension.--Subsection (c) of section 304 of the \nControlled Substances Act (21 U.S.C. 824) is amended--\n            (1) by striking the last two sentences in such subsection;\n            (2) by striking ``(c) Before'' and inserting ``(c)(1) \n        Before''; and\n            (3) by adding at the end the following:\n    ``(2) An order to show cause under paragraph (1) shall--\n            ``(A) contain a statement of the basis for the denial, \n        revocation, or suspension, including specific citations to any \n        laws or regulations alleged to be violated by the applicant or \n        registrant;\n            ``(B) direct the applicant or registrant to appear before \n        the Attorney General at a time and place stated in the order, \n        but no less than thirty days after the date of receipt of the \n        order; and\n            ``(C) notify the applicant or registrant of the opportunity \n        to submit a corrective action plan on or before the date of \n        appearance.\n    ``(3) Upon review of any corrective action plan submitted by an \napplicant or registrant pursuant to paragraph (2), the Attorney General \nshall determine whether denial, revocation or suspension proceedings \nshould be discontinued, or deferred for the purposes of modification, \namendment, or clarification to such plan.\n    ``(4) Proceedings to deny, revoke, or suspend shall be conducted \npursuant to this section in accordance with subchapter II of chapter 5 \nof title 5. Such proceedings shall be independent of, and not in lieu \nof, criminal prosecutions or other proceedings under this title or any \nother law of the United States.\n    ``(5) The requirements of this subsection shall not apply to the \nissuance of an immediate suspension order under subsection (d).''.\n\nSEC. 3. REPORT TO CONGRESS ON EFFECTS OF LAW ENFORCEMENT ACTIVITIES ON \n              PATIENT ACCESS TO MEDICATIONS.\n\n    (a) In General.--Not later than one year after the date of \nenactment of this Act, the Secretary of Health and Human Services, \nacting through the Commissioner of Food and Drugs and the Director of \nthe Centers for Disease Control and Prevention, and in consultation \nwith the Administrator of the Drug Enforcement Administration and the \nDirector of National Drug Control Policy, shall submit a report to the \nCommittees on the Judiciary of the House of Representatives, the \nCommittee on Energy and Commerce of the House of Representatives, the \nCommittee on the Judiciary of the Senate, and the Committee on Health, \nEducation, Labor and Pensions of the Senate identifying--\n            (1) obstacles to legitimate patient access to controlled \n        substances;\n            (2) issues with diversion of controlled substances; and\n            (3) how collaboration between Federal, State, local, and \n        tribal law enforcement agencies and the pharmaceutical industry \n        can benefit patients and prevent diversion and abuse of \n        controlled substances.\n    (b) Consultation.--The report under subsection (a) shall \nincorporate feedback and recommendations from the following:\n            (1) Patient groups.\n            (2) Pharmacies.\n            (3) Drug manufacturers.\n            (4) Common or contract carriers and warehousemen.\n            (5) Hospitals, physicians, and other health care providers.\n            (6) State attorneys general.\n            (7) Federal, State, local, and tribal law enforcement \n        agencies.\n            (8) Health insurance providers and entities that provide \n        pharmacy benefit management services on behalf of a health \n        insurance provider.\n            (9) Wholesale drug distributors.\n\n            Passed the House of Representatives July 29, 2014.\n\n            Attest:\n\n                                                 KAREN L. HAAS,\n\n                                                                 Clerk."
}